BeyondSpring is trading at $0.77 (-8.59%) on August 17, 2026, following its August 14 second-quarter results, which raised concern about financing the planned DUBLIN-4 Phase 3 trial.
- Reported a $1.8 million continuing-operations loss.
- Cash, cash equivalents, and short-term investments were $6.5 million, down from $12.6 million at December 31, 2025.
- Warned about difficulties raising necessary financing for the 442-patient trial.